These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8821514)

  • 21. Assessment of bioavailability of experimental controlled release microcapsules of nifedipine.
    Mallick S; Gupta BK; Ghosal SK
    Acta Pol Pharm; 2000; 57(3):175-80. PubMed ID: 11143705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets].
    Drabant S; Klebovich I; Gachályi B; Renczes G; Farsang C
    Acta Pharm Hung; 1998 Sep; 68(5):294-306. PubMed ID: 9805816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the effects of two modified release preparations of nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily--in the treatment of mild to moderate hypertension.
    Kirby BJ; Kitchin NR
    Int J Clin Pract; 1999; 53(5):339-43. PubMed ID: 10695096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Studies on oral sustained-release microspheres of nifedipine].
    Fu CD; Jiang XT; Hu JH; Wu W
    Yao Xue Xue Bao; 1996; 31(9):706-11. PubMed ID: 9863236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.
    Cainazzo MM; Pinetti D; Savino G; Bartiromo M; Forgione A; Bertolini A
    Drugs Exp Clin Res; 2005; 31(3):115-21. PubMed ID: 16033250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.
    Zhao Q; Janssens L; Verhaeghe T; Brashear HR; Truyen L
    Curr Med Res Opin; 2005 Oct; 21(10):1547-54. PubMed ID: 16238894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
    Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
    Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vivo verification of in vitro release specifications of a theophylline sustained-release preparation].
    von Nieciecki A; Fuchs WS; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):580-3. PubMed ID: 9676348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers.
    El-Masry SM; El-Khodary NM
    Drug Res (Stuttg); 2020 Feb; 70(2-03):91-96. PubMed ID: 31746448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application.
    Woodcock BG; Merz PG; Rietbrock S; Rudolph B; Pfleiderer S
    Arzneimittelforschung; 1993 Jul; 43(7):734-6. PubMed ID: 8369004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy and bioavailability of a sustained release nifedipine formulation.
    Piovella C
    Arzneimittelforschung; 1987 Jul; 37(7):832-5. PubMed ID: 3675679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo performance of controlled release pellets of diltiazem HCl.
    Nisarur-ur-Rahman ; K H Y; Jia Woei W
    Pak J Pharm Sci; 2005 Apr; 18(2):44-8. PubMed ID: 16431398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single dose study of the bioequivalence of two sustained-release theophylline formulations.
    Contreras J; Pérez N; González R; Ontivero E; López M
    Arzneimittelforschung; 1998 Mar; 48(3):259-62. PubMed ID: 9553683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biotransformation and bioequivalence of a new nifedipine preparation].
    Achtert G; Wisotzki R; Lutz D; Jaeger H
    Arzneimittelforschung; 1987 Nov; 37(11):1296-7. PubMed ID: 3440039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and bioequivalence study of two gemfibrozil preparations.
    Benkö S; Drabant S; Grézal G; Urmös I; Csörgö M; Klebovich I
    Arzneimittelforschung; 1997 Aug; 47(8):913-6. PubMed ID: 9296277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug.
    Doser K; Guserle R; Nitsche V; Arnold G
    Int J Clin Pharmacol Ther; 1996 Aug; 34(8):345-8. PubMed ID: 8864797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.